We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA issued a warning letter to Deserving Health International after an inspection of the drug manufacturer’s facility in Richmond, British Columbia in July revealed sterility problems, failure to verify the identity of drug components and other significant violations. Read More
The FDA is mandating a new class warning and labeling changes for all gadolinium-based contrast agents — as well as requiring manufacturers to conduct additional human and animal safety studies. Read More
The PTO’s Patent Trial and Appeal Board dismissed a patent owner’s claims of sovereign immunity from the proceedings — in a move that might have implications for Allergan’s Restasis patent case involving a Native American tribe that is currently pending before the board. Read More
In a result that could have far-reaching implications for brand-name drug manufacturers, the California Supreme Court unanimously ruled Novartis can be held liable for injuries caused by generics of its products. Read More
United Therapeutics agreed to pay $210 million to resolve Justice Department claims that the drugmaker collaborated with charity Caring Voice Coalition (CVC) to boost sales of United’s pulmonary arterial hypertension drug by illegally covering Medicare patients’ out-of-pocket costs. Read More
The FDA is requesting all NDA and ANDA holders to submit a one-time, written status report to the agency after reviewing the information published in the Orange Book. Read More
The FDA finalized its May 2015 guidance on how makers of immediate-release, solid, oral products can request waivers for subsequent in vivo bioavailability and bioequivalence studies. Read More
Sens. Chuck Grassley (R-Iowa) and Amy Klobuchar (D-Minn.) asked FDA Commissioner Scott Gottlieb in a Dec. 18 letter to clarify the agency’s policies on importing prescription drugs from Canada. Read More
Faster approvals of generics and biosimilars, along with other measures aimed at reducing prescription drug prices, will be ongoing FDA priorities in 2018. Read More
In this issue of Drug Industry Daily, we examine some of the FDA’s priorities for 2018 and what industry experts expect to happen. We already know the FDA’s priorities for 2018 will include ongoing efforts to reduce drug prices, speed approvals for generics, and increase patient engagement, according to FDA officials and expert observers. On the quality front, the agency will target data-integrity as part of its new ConOps initiative. The EMA, meanwhile, will be juggling its regulatory obligations with Brexit preparations and the transfer of its headquarters from London to Amsterdam. Read More